Non-Alcoholic Steatohepatitis Treatment Pipeline Review H2 2016

PUNE, INDIA, October 21, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/619306-non-alcoholic-steatohepatitis-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


Scope
- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
- The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects
- The report assesses Non-Alcoholic Steatohepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Non-Alcoholic Steatohepatitis Overview 12
Therapeutics Development 13
Pipeline Products for Non-Alcoholic Steatohepatitis - Overview 13
Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis 14
Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies 15
Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes 20
Non-Alcoholic Steatohepatitis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Non-Alcoholic Steatohepatitis - Products under Development by Companies 25
Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes 31
Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development 32
Akarna Therapeutics Ltd. 32
AlbireoPharma 33
Alnylam Pharmaceuticals, Inc. 34
Amunix Operating Inc. 35
Aquinox Pharmaceuticals Inc. 36
Arisaph Pharmaceuticals, Inc. 37
AstraZeneca Plc 38
BiOrion Technologies B.V. 39
Bird Rock Bio, Inc. 40
Boehringer Ingelheim GmbH 41
Bristol-Myers Squibb Company 42
Can-Fite BioPharma Ltd. 43
Cardax Pharmaceuticals, Inc. 44
Catabasis Pharmaceuticals, Inc. 45
Cerenis Therapeutics Holding SA 46
Conatus Pharmaceuticals Inc. 47
Connexios Life Sciences Pvt. Ltd. 48
Daiichi Sankyo Company, Limited 49
DURECT Corporation 50
Dynavax Technologies Corporation 51
Eli Lilly and Company 52
Enanta Pharmaceuticals, Inc. 53
Exicure, Inc. 54
Galectin Therapeutics, Inc. 55
Galmed Pharmaceuticals Ltd. 56
Genextra S.p.a. 57
Genfit SA 58
GenKyoTex S.A. 59
Gilead Sciences, Inc. 60
GRI Bio, Inc. 61
iCo Therapeutics Inc. 62
Immuron Limited 63

Access Report @ https://www.wiseguyreports.com/reports/619306-non-alcoholic-steatohepatitis-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.